

HE Dr. Volda Lawrence
Minister of Public Health
Ministry of Public Health
Brickdam, Stabroek
Georgetown
Republic of Guyana

22 November 2017

Decision Letter: Request for 2018 Renewal of Gavi support for Inactivated Polio Vaccine

Your Excellency,

I am writing in relation to Guyana's request for renewal of the New Vaccine Support (NVS) for Inactivated Polio Vaccine that was reviewed by Gavi Managing Directors on 25 October 2017.

Following the recommendations made by the Managing Directors, I am pleased to inform you that Gavi has **approved** Guyana's request to renew Gavi support for Inactivated Polio Vaccine for 2018, subject to several conditions and requirements as specified in the Appendices to this letter.

The Appendices include the following important information:

Appendix A: Guyana Support for Inactivated Polio Vaccine (IPV)

Appendix B: Guyana Support for Injection Safety Devices

Please do not hesitate to contact my colleague Mr Ricard Lacort Monte, Senior Country Manager for Guyana, at rlacort@gavi.org if you have any questions or concerns.

Sincerely yours,



Hind Khatib-Othman
Managing Director, Country Programmes

cc: Minister of Finance
Director of Planning, Ministry of Health
EPI Manager, Ministry of Health
WHO Country Representative
WHO AMRO/PAHO
UNICEF Country Representative
UNICEF Regional Office
UNICEF Programme Division

Decision Letter
Guyana - Support for Inactivated Polio Vaccine (IPV)

This Decision Letter sets out the Programme Terms of a Programme.

1. Country: Guyana			
2. Grant number: 18-GUY-25b-X			
3. Date of Decision Letter: 22/11/2017			
4. Date of the Partnership Framework Agreement: 05/02/2015			
5. Programme title: New Vaccine Support (NVS), IPV routine			
6. Vaccine type: Inactivated Polio Vaccine (IPV)			
7. Requested product presentation and formulation of vaccine¹: Inactivated Polio Vaccine, 5 doses per vial, LIQUID			
8. Programme duration²: 2015 - 2020			
9. Programme Budget (indicative): subject to the terms of the Partnership Framework Agreement <i>Please note that endorsed or approved amounts for 2019 will be communicated in due course, taking into account updated information on country requirements and following Gavi's review and approval processes.</i>			
	2015-2017	2018	Total³
Programme Budget (US\$)	113,000 ⁴	33,500	146,500
10. Vaccine introduction grant / Product switch grant: Not applicable			
11. Indicative Annual Amounts: subject to the terms of the Partnership Framework Agreement ⁵			
Type of supplies to be purchased with Gavi funds in each year	2018		
Number of IPV vaccines doses	16,200		
Annual Amounts (US\$)	33,500		
12. Procurement agency: PAHO			
13. Self-procurement: Not applicable			
14. Co-financing obligations: Not applicable Gavi's usual co-financing requirements do not apply to IPV. However, Guyana is encouraged to contribute to vaccine and/or supply costs for IPV.			
15. Operational support for campaigns: Not applicable			
16. Additional reporting requirements:			
Reports and other information	Due dates		
To prepare for the annual procurement of vaccines, Country shall submit the following information in May each year: number of children to be vaccinated, vaccine stock levels including buffer stock, wastage rates, any proposed changes in presentation or minimum co-financing levels and vaccines received.	15 May		
In accordance with applicable Gavi processes, Country shall report on programmatic and financial performance.	To be agreed with Secretariat		

¹ Please refer to section 18 for additional information on IPV presentation.

² This is the entire duration of the Programme.

³ This is the total amount endorsed by Gavi for 2015 to 2018.

⁴ This is the consolidated amount for all previous years. Annual amounts prior to 2017 include the costs of injection safety devices. Annual amounts for 2017 onwards include only vaccine costs and freight.

⁵ This is the amount that Gavi has approved.

Decision Letter
Guyana - Support for Injection safety devices

This Decision Letter sets out the Programme Terms of a Programme.

1. Country: Guyana			
2. Grant number: 17-GUY-32a-X; 18-GUY-32a-X			
3. Date of Decision Letter: 22/11/2017			
4. Date of the Partnership Framework Agreement: 05/02/2015			
5. Programme title: Injection safety devices ⁶			
6. Programme duration⁷: 2017 - 2018			
7. Programme budget (indicative): (subject to the terms of the Partnership Framework Agreement)			
	2017	2018	Total⁸
Programme Budget (US\$)	2,000	1,000	3,000
8. Indicative annual amounts: (subject to the terms of the Partnership Framework Agreement) ⁹			
Injection safety devices to be purchased with Gavi funds in each year, <u>by type of support</u>			
New Vaccine Support (NVS), Inactivated Polio Vaccine, 5 dose(s) per vial, LIQUID, Routine	2017	2018	
Number of AD syringes	17,200	17,600	
Number of safety boxes	200	200	
Annual Amounts for injection safety devices for Vaccine (US\$)	1,000	1,000	
9. Procurement agency: PAHO			
10. Self-procurement: Not applicable			
11. Co-financing obligations: Co-financing requirements are listed in the relevant vaccine Decision Letter.			

Signed by,
On behalf of Gavi

Hind Khatib-Othman
Managing Director, Country Programmes
22 November 2017

⁶ This does not include vaccines. *Esta no incluye vacunas*

⁷ This is the entire duration of the programme. *Esta es toda la duración del Programa*

⁸ Ceci est le montant approuvé par Gavi. *This is the amount that Gavi has approved.*

⁹ This is the amount that Gavi has approved. *Este es el monto aprobado por Gavi.*

17. Financial clarifications: Not applicable.

18. Other conditions: Not applicable

Due to unprecedented demand for IPV and the challenges to scale up production capacities, the global IPV supply is highly constrained and is unlikely to meet all country requirements in the short term. As a consequence, the actual presentation and number of doses shipped may differ from those specified in this Decision Letter. In order to mitigate these circumstances, you are strongly encouraged to optimally manage available supply and follow recommendations and guidelines from WHO and UNICEF to reduce vaccine wastage.

If Guyana envisages a switch in product presentation, it is encouraged to incorporate elements for both IPV presentations in your initial introduction preparations, in order to minimise the need for later interventions and facilitate the switch. In those circumstances, in principle, no product switch grant will be provided to Guyana.

Signed by,

On behalf of Gavi



Hind Khatib-Othman
Managing Director, Country Programmes
22 November 2017